BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 17
• 18
• 19
• 20
• 21
• 22
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• Business

  GW Pharmaceuticals Reports Fiscal Fourth Quarter 2017 and Year-End Financial Results and Operational Progress

  Cash and cash equivalents at 30 September 2017 of £241.2 million ($322.2 million) compared to £374.4 million as at 30 September 2016..

  December 4, 2017

   · 

  14 min read
• Drug Development

  Nabriva Therapeutics Announces Completion of Enrollment in LEAP 2, a Phase III Clinical Trial Evaluating Oral Lefamulin for the Treatment of Community-Acquired Bacterial Pneumonia in Adults

  Company remains on track to report topline results in Spring 2018.

  December 4, 2017

   · 

  7 min read
• 

  Deals

  The Cooper Companies Pays $80M for Paragon Vision Sciences

  Paragon had trailing twelve month revenues of approximately $15 million and is forecasted to grow low double digits over the coming years.

  December 4, 2017

   · 

  7 min read
• Drug Development

  Bayer Release: Updated Larotrectinib Pediatric Phase I Clinical Trial Data Demonstrates Response in TRK Fusion Cancers

  These data are being presented today at the AACR Special Conference on Pediatric Cancer Research in Atlanta.

  December 4, 2017

   · 

  4 min read
• Moffitt Cancer Center Treats First U.S. Patient With Newly FDA-Approved CAR-T Therapy

  As commercial use for Yescarta gets underway, Moffitt is actively enrolling eligible patients, with ten individuals awaiting treatment.

  December 4, 2017

   · 

  3 min read
• Business

  Acentrus Specialty Signs New Agreement With Pfizer Oncology

  Pfizer is the first supplier that has been extended an agreement for its limited distribution drug portfolio of oral oncolytics by Acentrus.

  December 4, 2017

   · 

  2 min read
• Drug Development

  Lakewood-Amedex Advances Bisphosphocin Nu-8 to IND-Enabling Studies to Treat Complicated Urinary Tract Infection

  Lakewood-Amedex today announced that it will be advancing a second Bisphosphocin drug candidate, Nu-8, into preclinical IND-enabling studies.

  December 4, 2017

   · 

  3 min read
• Valeant Pharma Announces Launch of Private Offering of Senior Notes

  The Company also announced today that it has provided notice to its lenders of its intent to repay $175M of amounts outstanding under its revolving credit facility this week, using cash on hand.

  December 4, 2017

   · 

  3 min read
• Valeant Pharma and One of its Subsidiaries Commence Cash Tender Offers for Up to $1,000,000,000 Outstanding Principal Amount

  Valeant is the Offeror for the notes issued by it, and VPI is the Offeror for the notes issued by it.

  December 4, 2017

   · 

  12 min read
• Drug Development

  Ovid Therapeutics Presents New Data Demonstrating Potential of TAK-935/OV935 as a Novel Treatment for Developmental and Epileptic Encephalopathies at the American Epilepsy Society (AES) Annual Meeting

  The data were presented at the American Epilepsy Society 71st Annual Meeting, taking place December 1-5, 2017, at the Walter E. Washington Convention Center in Washington, D.C.

  December 4, 2017

   · 

  10 min read